Inicio・Lista de Acciones・Vaxcyte Inc

Vaxcyte Inc

Abierto

SectorSanidad

58.03 -1.01

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

56.95

Máximo

60.14

Métricas clave
By Trading Economics
Ingresos	-284M -605M
BPA	-1.97
Empleados	507
EBITDA	22M -292M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+94.24% upside

Dividendos
By Acuity
Próximas Ganancias	2 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	944M 8.7B
Apertura anterior	59.04
Cierre anterior	58.03

Noticias sobre sentimiento de mercado

By Acuity

50%

171 / 340 Clasificación en Healthcare

Vaxcyte Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 ago 2026, 19:46 UTC

Vaxcyte Inc shares are higher today, supported by broader market gains following positive sentiment from the recent inflation report. The stock remains above its 20-day moving average.

11 ago 2026, 23:11 UTC

Vaxcyte Inc shares are higher in after-market trading, reflecting positive momentum despite no specific news driving the price action.

10 ago 2026, 19:56 UTC

Vaxcyte Inc shares are higher, continuing gains since Friday's close, reaching a peak earlier in the session. No specific news was identified for the move.

7 ago 2026, 21:01 UTC

Vaxcyte Inc shares are lower in after-market hours, continuing a weak trading session without any specific news to explain the decline.

6 ago 2026, 20:03 UTC

News

Vaxcyte reports a net loss of $284.3 million for Q2. Shares are trading higher as the company anticipates key Phase 3 trial data in 2027.

5 ago 2026, 19:16 UTC

Vaxcyte Inc. shares are higher today, aligning with broader market trends, despite no specific news identified. The stock remains near its one-month range low.

4 ago 2026, 20:21 UTC

Vaxcyte Inc. shares are lower in after-market trading, remaining flat since Tuesday's close and positioned below its 20-day moving average.

3 ago 2026, 19:46 UTC

Vaxcyte Inc's shares are lower today, continuing a decline since Friday. The stock is trading near the lower end of its one-month range.

31 jul 2026, 19:56 UTC

Correlated Moves

Shares lower amid broader sector sentiment; SPDR S&P Biotech ETF declines.

30 jul 2026, 18:52 UTC

Vaxcyte Inc's shares are higher today amid strong buying activity, reaching an intraday high but remain below the 20-day moving average.

29 jul 2026, 18:23 UTC

Vaxcyte Inc is lower in Wednesday's session, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

28 jul 2026, 18:46 UTC

Vaxcyte Inc. shares are trading lower amid broader market trends and volatility, remaining below the 20-day moving average as bond yields decline.

27 jul 2026, 19:46 UTC

Vaxcyte Inc shares are trading higher today, despite earlier declines and without specific company news. Broader market volatility is influenced by falling crude oil prices.

23 jul 2026, 19:16 UTC

Vaxcyte Inc shares are lower today amid a broader decline in tech stocks following earnings reports from Alphabet and Tesla. No specific news was identified.

21 jul 2026, 18:26 UTC

Vaxcyte Inc is trading higher today, continuing its advance since Monday's close. This movement occurs despite concerns over rising treasury yields and geopolitical tensions.

Comparación entre iguales

Cambio de precio

Vaxcyte Inc previsión

Precio Objetivo

By TipRanks

94.24% repunte

Estimación a 12 Meses

Media 114.33 USD 94.24%

Máximo 163 USD

Mínimo 75 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Vaxcyte Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Vaxcyte Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

171 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.